New permanent tax exclusions and expanded funds usage give benefit leaders the opportunity to bolster their financial ...

Minister for Health Carroll MacNeill said that Wegovy will be available as early as the end of 2025 as part of the HSE’s ...

New Jersey’s public health insurance system is hemorrhaging. We're about to feel the pain. Public workers and taxpayers deserve better.

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Dr Bryan Betty joined Jack Tame to discuss Wegovy – what it is, how you use it, the side effects, and why people are seeking medical treatment for their weight. A once-weekly injection for weight loss ...

The preventative healthcare measures recommended in the Scotland’s Population Health Framework 2025-2035 plan have been ...